Alliance Global Partners cut shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) from a buy rating to a neutral rating in a research note released on Monday morning, The Fly reports. The brokerage currently has $4.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $11.00.
A number of other brokerages also recently issued reports on ALIM. StockNews.com began coverage on Alimera Sciences in a research report on Monday. They set a hold rating on the stock. HC Wainwright upped their price target on Alimera Sciences from $8.00 to $9.00 and gave the stock a buy rating in a research report on Thursday, July 28th.
Alimera Sciences Trading Down 0.4 %
Shares of ALIM stock opened at $4.19 on Monday. The business’s fifty day simple moving average is $5.21 and its 200-day simple moving average is $5.64. The company has a market cap of $29.34 million, a PE ratio of -1.59 and a beta of 1.38. Alimera Sciences has a 12-month low of $3.94 and a 12-month high of $7.92.
Institutional Investors Weigh In On Alimera Sciences
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.